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JOHN R. LITZOW,t JACOB LEMANN, JR., AND EDWARD J. LENNON t
(From the Departme-ht of Internal Medicine and the Clinical Research Center, Marquette
University School of Medicine, and the Milwaukee County General Hospital,
Milwaukee, Wisc.)
Summary. Small but statistically significant negative calcium balances were
found in each of eight studies in seven patients with chronic azotemic renal
disease when stable metabolic acidosis was present. Only small quantities
of calcium were excreted in the urine, but fecal calcium excretion equaled or
exceeded dietary intake. Complete and continuous correction of acidosis by
NaHCO3 therapy reduced both urinary and fecal calcium excretion and pro-
duced a daily calcium balance indistinguishable from zero.
Apparent acid retention was found throughout the studies during acidosis,
despite no further reduction of the serum bicarbonate concentration. The
negative calcium balances that accompanied acid retention support the sug-
gestion that slow titration of alkaline bone salts provides an additional buffer
reservoir in chronic metabolic acidosis. The treatment of metabolic acidosis
prevented further calcium losses but did not induce net calcium retention. It
is suggested that the normal homeostatic responses of the body to the altera-
tions in ionized calcium and calcium distribution produced by raising the
serum bicarbonate might paradoxically retard the repair of skeletal calcium
deficits.
Introduction
Skeletal abnormalities may occur in the course
of chronic azotemic renal disease. Osteomalacia,
osteitis fibrosa, and osteosclerosis may be recog-
nized by X ray, singly or in combination, and are
found with greater frequency on histologic ex-
amination of bone (1-3). Chronic metabolic
acidosis, acquired vitamin D resistance, and sec-
ondary hyperparathyroidism have each been con-
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sidered a factor in the pathogenesis of these dis-
orders (1, 4, 5).
The role of metabolic acidosis has not been
critically tested. Although Albright and Reifen-
stein considered acidosis the major cause of azo-
temic bone disease (4), other studies (2, 5, 6)
have failed to find calcium retention after alkali
therapy. Such studies have often been brief, and
alkali therapy has frequently been continued while
other forms of therapy were evaluated.
We carried out the present studies to determine
whether the continuous and complete correction
of the acidosis of chronic renal disease had any
significant influence on calcium balance.
Methods
Eight paired metabolic balance studies were carried
out in seven patients with chronic azotemic renal dis-
ease during periods of spontaneous but stable acidosis
and during periods when the serum bicarbonate con-
centration was maintained at stable normal levels by the
continuous administration of sodium bicarbonate. None
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of the subj ects' serum bicarbonate concentrations changed
by more than + 1 mEq per L on the eight or more deter-
minations during each of the separate parts of the paired
studies. Each phase of the study of every patient con-
sisted of three or four consecutive 6-day metabolic pe-
riods. All patients were hospitalized in the Clinical Re-
search Center, Marquette University School of Medi-
cine, and each patient ate a constant diet. Six of the
studies were carried out first while the patient was aci-
dotic and then repeated after at least 2 weeks of NaHCO3
therapy. Two studies were carried out in patients who
had been receiving adequate NaHCO3 therapy for many
months and were repeated several weeks after alkali
therapy had been stopped. Table I presents the perti-
nent clinical data for each patient. All but one had ra-
diographic evidence of slight diffuse demineralization of
bone, and three had changes consistent with secondary
hyperparathyroidism (subperiosteal bone resorption in
phalanges). None had significant bacteriuria.
Each patient was allowed 3 to 6 days to adapt to his
constant diet before balance observations were begun.
The diets were typical of ordinary American diets and
were adjusted to the patient's customary food intake.
Duplicate daily diets were prepared and analyzed on eight
to twelve occasions during each study. The average co-
efficient of variation for the analyses of each diet constitu-
ent was as follows: Na, ± 4.1%o; K, ± 4.4%o; Ca, ± 4.2%o;
Mg, +4.3%o; Cl, + 4.0%o; and P, ± 4.7%o.
The constant daily doses of NaHCO3 required to main-
tain normal stable serum bicarbonate levels were weighed
on an analytical balance and administered in gelatin cap-
sules in four divided daily doses. Sodium bicarbonate
doses of 61 to 180 mEq per day were required to main-
tain normal serum bicarbonate levels because of the vari-
able reduction in renal tubular reabsorptive threshold for
bicarbonate in patients with renal disease (7). Each pa-
tient received one multivitamin capsule daily containing
1,000 USP U of vitamin D.
In five paired studies the patients were given 10.0 mEq
of stable strontium as the gluconate 1 intravenously at
the beginning of a metabolic period while acidotic and
again when the serum bicarbonate was kept at steady
normal levels by NaHCO3 therapy. Strontium was mea-
sured in serum, urine, and fecal ash by atomic absorp-
tion spectrophotometry with lanthanum in the diluent to
suppress anionic interference. We carried out all stron-
tium analyses for both phases of the study of each pa-
tient simultaneously to minimize analytical variability.
Strontium was administered with the intention of esti-
mating calcium turnover in bone by the method described
by Fraser, Harrison, and Ibbertson (8). The validity
of the use of strontium as a tracer for bone calcium
turnover has been documented by other investigators
(9, 10) as well. The calculations used by Fraser and
co-workers (8) depend upon the fact that normal sub-
jects excrete most of an injected dose of strontium in
the urine. In their studies, normal subjects excreted only
8 to 16%o of a 10-mEq intravenous dose of strontium in
1 Kindly supplied by Dr. C. D. Burrell, Sandoz Phar-
maceuticals, Hanover, N. J.
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TABLE II
Average blood and serum measurements
Acidosis Alkali therapy *Pt
Whole blood
H+ nEq/L 49.3 i 3.6 40.6 + 3.6 -8.7 + 3.0 <0.001
(pH 7.31) (pH 7.39)
Serum
HCO3- mEqIL 18.7 i 3.2 27.4 ± 2.1 +8.7 ± 3.5 <0.001
PCo2t mm Hg 38 i 6 46 i 2 +8 ± 7 <0.025
Na mEqIL 139 ± 3 140 i 2 +1 i 3 NS
K mEqIL 4.8 i 0.9 4.6 4 0.9 -0.2 ± 0.4 NS
Cl mEqIL 108 ± 3 98 ± 6 -10 ± 6 <0.005
Unmeasured anion§ mEqIL 10 i 3 14 i 5 +4 ± 4 <0.05
Ca mEqIL 4.4 ± 0.6 4.4 i 0.9 0 i 0.4 NS
P mg/100 ml 5.7 ± 1.1 5.9 ± 1.6 +0.2 i 1 NS
Mg mEq/L 2.1 0.2 2.1 0.2 0 ±0.2 NS
Creatinine mg/100 ml 8.0 ± 3.5 8.4 ± 3.8 +0.4 ± 2.0 NS
* A = Value during sodium bicarbonate therapy minus value during acidosis.
t Probability that the mean change is not different from zero.
t CO2 pressure.§ [Na+] - ([Cl-] + [HCO3-J).
the feces during the first 6 days after injection, and this
was neglected in their kinetic analyses. Studies in our
laboratory of two normal subjects who were given 10
mEq of strontium intravenously showed that they ex-
creted 33 and 38%o of the dose in the urine in 6 days and
8 and 10%o in the feces during the same period. By con-
trast, the patients with renal disease excreted, at most,
14% of the dose of strontium in the urine while excreting
as much of the dose in the feces as did normal subj ects.
Thus, kinetic analyses of these data could not be car-
ried out because strontium was excreted primarily in
TABLE III
Mean daily diet and stool composition
Acidosis Alkali therapy
Diet
Na mEq 131 ± 29* 68 ± 10*
K mEq 63± 8 67±10
Ca mEq 27 ± 14 28 ± 14
Mg mEq 19 ± 3 204 3
Cl mEq 130 ± 30 68 12
P mmoles 31 i 7 32± 7
Stool
Weight g 92 ± 47 94 ± 39
Na mEq 2 ± 2 2 ± 2
K mEq 10± 4 11 ± 5
Ca mEq 304 16 28 ± 15
Mg mEq 14 ± 4 14 ± 4
Cl mEq 1i1 1I 1
P mmoles 14 + 5 14 ± 6
* These values are the sodium content of the basic diets.
During acidosis, an average of 6 additional mEq of sodium
per day was fed as bicarbonate because two patients
required small daily doses of bicarbonate to prevent
symptomatic acidosis. During treatment an average of
107 mEq NaHCO3 was fed each day in addition to the
basic diet.
the feces, and the excretion into the gut on a given day
of the study could not be determined accurately because
of the variable lag between fecal formation and defeca-
tion. Nevertheless, it was possible to compare the
amount of strontium retained in the body 6 days after
injection and the corresponding serum strontium con-
centrations in the same subject before and after treat-
ment of acidosis. Alkali therapy had no apparent effect
on the frequency of defecation or the quantity of feces
excreted per 6-day metabolic period. During those pe-
riods in which strontium was injected, average daily
stool weight was 119 ± 38 g during acidosis and 116±
30 g during alkali therapy.
All other procedures, analytical methods, and calcula-
tions have been described in a previous publication (11).
As in our earlier studies, carmine markers were used to
delineate stool periods. All experimental results are
presented as mean values ± 1 SD.
Results
The average concentrations of blood and serum
constituents during stable acidosis and after bi-
carbonate therapy are presented in Table II.
Alkali therapy significantly reduced blood [H+]
and raised serum [HCO3-]. Compensatory re-
ductions in CO2 pressure (Pco,) and [CF] oc-
curred. "Unmeasured anions" 2 rose significantly,
presumably because the anionic charges of the se-
rum proteins increased. The remaining electrolyte
concentrations and the serum creatinine concen-
trations did not change.
The mean values for the diet analyses are shown
in the upper part of Table III. Sodium and
2 [Na+] - [CI-] + [HCO3-]).
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TABLE IV
Mean daily mineral balances and change in body weight
Acidosis Alkali therapy Pt
Na mEq +17 :1 15 +12 ± 15 - 5 ± 18 NS
K mEq + 3 ±6 + 3 ± 4 0 ± 3 NS
Mg mEq + 1 ±4 + 1 ±t 2 0 ±t 3 NS
Cl mEq +13 ±15 + 2 ± 5 -11 ±14 NS
P mmoles + 2 ±2 +1 i 3 -1 i 2 NS
Weight change kg/day + 0.06 ± 0.05 + 0.02 i 0.05 - 0.04 i 0.09 NS
* Value during sodium bicarbonate therapy minus value during acidosis.
t Probability that the mean change is not different from zero.
chloride intakes differed in the two parts of each
study because the quantity of NaCl added to the
diets was reduced when NaHCO3 therapy was
begun. The mean values for the remainder of the
diet analyses were not different. The mean stool
weight and fecal electrolyte contents are shown
in the lower part of Table III. No significant
changes occurred.
The average changes in body weight and the
mean balances of Na, K, Mg, Cl, and P during
acidosis and after alkali therapy are presented in
Table IV. No significant changes were found.
The most pertinent findings in each of the paired
studies are shown in Table V. The values given
for each patient during acidosis and during alkali
therapy are the means of all metabolic periods ob-
served in that study. The first three columns
show that mild to moderate acidosis was present
in each patient before therapy, and that the se-
rum [HCO3-] was normal during NaHCO3
therapy. The mean change in serum [HCO.-]
after alkali therapy was + 8.7 + 3.5 mEq per L
(p < 0.001). The effect of alkali therapy on cal-
cium balance is shown in the next three columns.
During acidosis, small negative calcium balances
were observed in each study, averaging - 5.3 +
3.8 mEq per day. This differed significantly from
zero balance (p < 0.01). With NaHCO3 therapy,
calcium balance was less negative in six of the
eight studies, and, for the group, was no longer
significantly different from zero balance (p > 0.3).
The mean change in calcium balance after alkali
therapy was significant (p = 0.025). The uri-
nary calcium excretion (not shown in the Table)
was very low in both parts of each study, averag-
ing 1.7 + 0.9 mEq per day during acidosis and
1.5 + 0.9 mEq per day during alkali therapy.
The next three columns of Table V give the per
cent of a 10-mEq intravenous dose of strontium
retained 6 days after injection in each of five pa-
tients while acidotic and again after NaHCO3
therapy. Each patient retained more of the
strontium after alkali therapy; despite this the
serum concentration of strontium 6 days after ad-
ministration (shown in the next three columns)
was lower. The cumulative urinary strontium
excretion (not shown in the Table) was low, av-
eraging 9 + 5% of the dose during acidosis and
6 + 3% during alkali therapy. Most of the stron-
tium appeared in the feces (18± 6% of the dose
during acidosis and 12 + 3% when the serum bi-
carbonate was normal).
The final three columns of Table V show the ap-
parent net external acid balances, calculated as
described previously (11). The mean acid bal-
ance in each phase of the studies was not signifi-
cantly different from zero, but the change in acid
balance between the paired studies was signifi-
cant (p < 0.01). In seven of the eight studies
acid balance was less positive during alkali therapy.
The parameters of acid balance for the group
are presented in Table VI. During alkali therapy,
the sum of urinary S4O and organic acid salts
increased significantly, due entirely to an in-
crease in the amount of total organic acids exist-
ing as anions in the more alkaline urines. The
calculated dietary and stool combustible anions
were unchanged. Net fixed acid production, in-
cluding the NaHCO3 administered, was signifi-
cantly reduced. Renal acid excretion also fell
significantly as a result of losses of bicarbonate
in the urine during alkali therapy. However, the
reduction in acid excretion during alkali therapy
was not so great as the reduction in acid produc-
tion, and thus the acid balance was significantly
less positive.
283
J. R. LITZOW, J. LEMANN, JR., AND E. J. LENNON
C000 m C4 eq 0s 0 -f O
iC C4 -4 0
+I O
r- r- M O ao D _- - °
+ + + C4 °A
I++
_-r
II
0- _-' o
000000)
-H
0
u:
0
0
0R
0
0
-H
~o
R
0
0C
-H
r-
+
-H
ON
A
to
V
0
Vin
-H
00 0 s N 00 0
0- C4' 0 -i-a
+I+ + ++ +
MeON to N o o N
+I+ ++ +
00) t - CO 0
U4 0 Qb rz o ux; 11 4 t
1 N o4M "
oC 0w 00 N
_. _4 N _4 _ _4 _ N
00
110
00
+
Ci
-H '
i0
coo
"iO.H oR
ui V
vi
M-11H0
co
r-
-H
co
Cd
CU
0.
0
0
u
Cb
CU.1C'
0
z
CU
._
CU
*_ Cd
-~a
0
CU
33. 0
co
0d
>
.o
0
CU
U_
0d +
o
QC ._
*_ (n c
O
o co
o
3 CdEW
rC
*E " * + 2°
Cd UY
CU-.
cdE d7S' cd3.
.0
°CCd &.
._CUO
> u
* we
Discussion
A negative calcium balance was found in each
patient with chronic azotemic renal disease when
stable metabolic acidosis was present. As in other
studies of calcium metabolism in azotemic sub-
jects, the patients excreted only very small quan-
tities of calcium in the urine (12), but fecal cal-
cium content equaled or exceeded dietary calcium
intake (2, 5, 6). The daily losses of calcium were
small, averaging - 5.3 3.8 mEq, but statistically
different from zero balance (p < 0.01). It is
likely that such losses are also physiologically sig-
nificant when the potential duration of azotemic
acidosis is considered. Projected over 10 years,
the daily loss of 5 mEq of calcium would expend
nearly one-third of the total calcium contained in
the skeleton of an average adult.
When the acidosis was completely corrected by
continuous sodium bicarbonate therapy, calcium
losses from the body were significantly reduced,
although no detectable change in total serum cal-
cium concentration was found. In addition, in-
creased retention of intravenously administered
strontium occurred despite lower serum strontium
levels.
These results suggest that the correction of
metabolic acidosis accelerated the rate at which
calcium and strontium left the extracellular fluid
and entered some other tissue, presumably bone.
With alkali therapy, the rates at which calcium
entered and left bone apparently became equal,
since external calcium balance was restored to
zero.
These studies, while indicating that alkali ther-
apy alone can prevent continuing losses of calcium
in chronic azotemic acidosis, confirm the findings
of others (2, 5, 6) that such therapy fails to in-
duce absolute calcium retention. Many investi-
gators (2, 5, 6) have observed far more impressive
calcium retention in patients with renal disease
treated with pharmacologic doses of vitamin D,
and a state of acquired vitamin D resistance is
now generally accepted as a feature of chronic
azotemia. However, a similar failure to repair
induced calcium deficits has been found in normal
subjects recovering from experimental NH4Cl
acidosis (13, 14). It is thus conceivable that nor-
mal homeostatic responses evoked by the correc-
tion of metabolic acidosis might in some way delay
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TABLE VI
The parameters of the acid balance
Acidosis Alkali therapy At P*
mEq/day
Urinary S04 + OA salts 61 i: 13 67 i 11 + 6 -t 6 <0.05
Diet combustible anions* 54 i 10 56 i 12 + 2 i 7 NS
Stool combustible anions* 29 ±t 8 28 i 6 - 1 ± 4 NS
NaHCO3 fed 6 107 +101
Net fixed acid production +30 i 20 -68 :1: 40 - 98 ± 34 <0.001
Renal acid excretion 20 i 11 -66 4- 32 - 86 i 30 <0.001
Acid balance +10± 13 - 2 i 15 - 12 ± 9 <0.01
* (Na+ + K+ + Ca++ + Mg++) - (Cl- + 1.8 mmoles P).
t A = values during sodium bicarbonate therapy minus values during acidosis.
T Probability that the mean change is not different from zero.
skeletal remineralization. As Heaney has re-
cently stressed (15), the hormonal control of cal-
cium metabolism in the adult appears to defend
primarily the ionized calcium concentration of
body fluids. When metabolic acidosis is treated
with alkali, both redeposition of calcium in bone
and an increased affinity of plasma proteins for
calcium would tend to lower the serum ionized
calcium concentration. This change would pre-
sumably be opposed by increased parathyroid hor-
mone secretion, with a resultant increase in in-
testinal and renal tubular calcium reabsorption,
but also an increased mobilization of calcium from
bone. The effect of parathyroid hormone on bone
itself, although aiding in the stabilization of the
blood ionized calcium concentration, would para-
doxically retard the repair of skeletal calcium defi-
cits. By contrast, the primary action of pharma-
cologic doses of vitamin D (2, 5, 6) or massive
oral administration of calcium salts (16) would
be to increase intestinal calcium absorption. In
this circumstance, serum ionized calcium would
tend to rise, parathyroid hormone secretion would
decrease, and deposition of calcium in bone would
be favored.
Regardless of the intimate mechanisms, the re-
sults of the present studies are consistent with a
previous suggestion (17) that slow losses of cal-
cium from the skeleton might occur in chronic
azotemic renal disease while acidosis was present,
but not when the acidosis was adequately treated.
As in earlier investigations (17, 18), an apparent
continuing retention of acid was found during pe-
riods when the serum [HCOQ-] was reduced but
stable. If it is assumed that the actual acid balance
was zero during alkali therapy (18), the apparent
acid retention during acidosis averaged 12 + 9
mEq per day. The simultaneous losses of calcium,
regardless of the salts from which they arose,
could not account for the retention of this quan-
tity of acid. It is most likely that this quantitative
discrepancy resulted from difficulties inherent in
calculating acid production when whole food diets
were used ( 11). An alternative possibility is that
the valence of phosphorus in the feces increased
significantly during acidosis in these azotemic pa-
tients, and fecal losses of combustible anions were
thus overestimated.
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